X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.globenewswire.com//news-release/2023/10/30/2769158/37704/en/CytomX-Therapeutics-to-Present-Preclinical-Data-for-Conditionally-Activated-Interferon-Alpha-2b-at-the-SITC-2023-Annual-Meeting.html
https://www.pharmacompass.com/pdf/news/betterlife-initiates-preclinical-study-of-ap-003-in-delta-variant-of-sars-cov-2-1631603417.pdf
https://www.aoporphan.com/se_en/our-company/newsroom/aop-orphan-pharmaceuticals-presents-latest-analysis-on-besremi-r-ropeginterferon-alfa-2b-in-polycythaemia-vera-at-the-prestigious-european-hematology-association-eha-annual-meeting-2021
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103949
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103949
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103949
http://www.pharmatimes.com/news/seven_medicines_leap_closer_to_eu_approval_1272896
https://www.prnewswire.com/news-releases/pharmaessentia-and-aop-orphan-receive-positive-chmp-opinion-for-besremi-ropeginterferon-alfa-2b-for-treatment-of-polycythemia-vera-pv-in-eu-300767190.html
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103132
http://www.biopharma-reporter.com/Markets-Regulations/Russia-approves-first-ever-biosimilar-of-Serono-s-MS-drug-Rebif
http://portal.anvisa.gov.br/wps/content/anvisa+portal/anvisa/sala+de+imprensa/menu+-+noticias+anos/2015/anvisa++suspende+a+importacao+de+insumos+chineses
http://www.business-standard.com/article/pti-stories/roche-cuts-hepatitis-c-drug-cost-by-65-for-govt-institutions-115061201051_1.html
http://www.fiercepharma.com/story/ca-panel-gileads-harvoni-cost-effective-95k-only-affordable-half-price/2014-12-15
http://www.Prnewswire.com/news-releases/class-action-lawsuit-challenges-the-exorbitant-pricing-of-gileads-hepatitis-c-drug-sovaldi-300007372.html
Market Place
Share 
